Lisa Henderson

Gilead's pricing of COVID drug remdesivir is a reminder of pharma's tenuous path forward as it seeks a more holistic image makeover.

Welcome to the new look and branding of Pharmaceutical Executive-reimagined to better reflect you, our audience, and expand on the content you've long trusted us to deliver.

Speculating the downstream impact on industry practices is just that right now-speculation. What is sure is some things will never be the same, and some things could even get better.

Amid concerns over a potential 'wild west' climate for data analytics in pharma, taking a long-term, proactive, and enterprise view of your company’s data may be the best way to keep your organization and reputation safe.

Amid the growth but still-cautious embrace of social media and other digital marketing channels, appealing to the younger physician requires a nuanced approach-mixing proven expertise with fresh ideas.

Veteran pharma leader Jay Galeota shares learnings and perspectives from an off-the-beaten-path career rise-one driven today by a mission to align the industry’s risk-taking approach across the entire drug life cycle.

With the nomination period for our latest Emerging Pharma Leaders selections in full swing, it's a good reminder that the industry's future path ultimately depends on its leaders, emerging and otherwise.

While drug pricing remains a top topic in the media at large and worthy of continuous exploration, we shift away in our latest pharma trends report, instead spotlighting seven key themes that we think are a bit less unpredictable in the months ahead.

Led in part by its new head of the Americas business, Sebastian Guth, Bayer went all in in 2019 on expanding pursuits in science and discovery, striking deals with 11 digital health startups and upping investment in disease-detection programs and patient engagement and education.

With so many different rationales for drug pricing and “value” continuing to feed the debate, the market access function in healthcare must clearly tackle these issues-but at what cost to the patient?

The industry’s quest to get a handle on the cost-shift implications of these new programs and the risks for patient access and pharma’s bottom line.

Though uncertain market dynamics remain at play, the current magnitude of innovation in biopharma is staggering, and, at times, overwhelming.

With pursuits of complex therapies more routine, biotech platform companies are tasked with aligning their science with process and manufacturing proficiency to stand out in an increasingly crowded investment field.

Sebastian Guth, President of Pharmaceuticals, Americas Region for Bayer, shares the company's long-term vision.

Amid new findings on today’s C-suite mood and approach to digital transformation, experts-in a panel discussion and wider examinations by Pharm Exec editors-explore the intersection of data and technology and the areas that must evolve to meet the digital health demands of tomorrow.

Our quest to make sense of a complex future data ecosystem in pharma.

In keeping pace with the digital transformation, pharma companies are doing pretty well with data and infrastructure, but a fundamental reshaping of operating models remains the biggest hurdle to moving forward.

Bernhardt Zeiher, Chief Medical Officer of Astellas discusses how the company transitioned from a traditional R&D approach to a platform approach, the need for innovation models to change in pharma, and the impact academia has on drug development.

Janssen’s company group chairman of Europe, Middle East, and Africa operations, Kris Sterkens speaks with Pharm Exec editors. Kris talks about his finance background, global pricing issues, and challenges and opportunities for EMEA biopharma breaking into the US market.

There are many factors involved in launching a drug but one prevailing goal: brand awareness. I caught up with Fingerpaint's Bryan O’Malley, who shared some of today's key digital trends affecting that mission.

Apellis’ CEO and co-founder, Dr. Cedric Francois talks with Pharm Exec editors about his journey from clinical work to creating biotech startups, which has included research, clinical work, and the launch of two startups.

In a sit-down with editors from our group publications, former FDA Commissioner Scott Gottlieb chatted with Pharm Exec on several topics, including the evolution of pricing and reimbursement for novel therapies-and the access fixes needed for future.

Pharm Exec editors sit down with Mark Velleca, CEO of G1 Therapeutics. In this episode, Mark talks about how he differentiates himself in the oncology field, why he considers G1 Therapeutics an "old school company," and about the North Carolina biotech landscape.

Pharm Exec editors share insights into what they've been working on this summer for the June, July, and August issues; plus a sneak peek into what's coming in September!

How one company’s cultural transformation aims to strengthen and empower its talent base.

Pharm Exec sits down with a pair of big pharma compliance leaders to discuss the strategic move to principles-based policies and the impact of other emerging forces influencing industry compliance practice.

Robert Finkel, the CEO of The FreshBlood Group talks with Pharm Exec editors about the positives and negatives of pharma’s marketing needs, the details and evolution around founding The FreshBlood Group, and how emerging pharma and biotech companies can budget in successful marketing.

Highlighting the biggest observations from this year's DIA Annual Meeting-topics likely to continue to dominate industry headlines for the foreseeable future.